Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin

被引：0
|
作者：
Tepper, P. [1 ]
Mardekian, J. [2 ]
Masseria, C. [2 ]
Phatak, H. [3 ]
Kamble, S. [3 ]
Abdulsattar, Y. [2 ]
Petkun, W. [3 ]
Lip, G. Y. H. [4 ]
机构：
[1] Univ Pittsburgh, Epidemiol, Pittsburgh, PA USA
[2] Pfizer Inc, New York, NY USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Univ Birmingham, Birmingham, W Midlands, England
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1975
引用
收藏
页码：339 / 339
页数：1
相关论文
共 50 条
  • [31] Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
    Berger, Jeffrey S.
    Laliberte, Francois
    Kharat, Akshay
    Lejeune, Dominique
    Moore, Kenneth Todd
    Jung, Young
    Lefebvre, Patrick
    Ashton, Veronica
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (06) : 881 - 890
  • [32] Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
    Abdullah, Ahmad Salihin
    Tan, Hwee Pheng
    Mohd Saffian, Shamin
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2022, 29 (02): : 164 - 172
  • [33] Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
    Yang, Lanting
    Brooks, Maria M.
    Glynn, Nancy W.
    Zhang, Yuting
    Saba, Samir
    Hernandez, Inmaculada
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 126 : 29 - 36
  • [34] Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review
    Deitelzweig, Steve
    Lip, Gregory Y. H.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 243 - 244
  • [35] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    BLOOD, 2012, 120 (21)
  • [36] Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
    Norby, Faye L.
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Chamberlain, Alanna M.
    Rapson, Ian
    Alonso, Alvaro
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [37] Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
    Faye L. Norby
    Lindsay G.S. Bengtson
    Pamela L. Lutsey
    Lin Y. Chen
    Richard F. MacLehose
    Alanna M. Chamberlain
    Ian Rapson
    Alvaro Alonso
    BMC Cardiovascular Disorders, 17
  • [38] COST EFFECTIVENESS OF ORAL ANTICOAGULATION THERAPY FOR NON-VALVULAR ATRIAL FIBRILLATION PATIENTS: WARFARIN VERSUS THE NEW ORAL ANTICOAGULANTS RIVAROXABAN, DABIGATRAN AND APIXABAN
    Ortiz-Cartagena, Ismael
    Gotay, Antonio Orraca
    Acevedo, Jose
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 490 - 490
  • [39] Effectiveness and Safety of Dabigatran and Warfarin in Real-World US Patients With Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study
    Lauffenburger, Julie C.
    Farley, Joel F.
    Gehi, Anil K.
    Rhoney, Denise H.
    Brookhart, M. Alan
    Fang, Gang
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (04):
  • [40] Value-based pricing for dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation in Germany
    Krejczy, M.
    Marx, S.
    Obermann, K.
    Wehling, M.
    Harenberg, J.
    EUROPEAN HEART JOURNAL, 2012, 33 : 815 - 815
12345